Skip to main content

Table 4 Annual FVC changes between the treatment and non-treatment groups in one year after the antigen avoidance test

From: Impact of antigen avoidance test for fibrotic hypersensitivity pneumonitis in stable phase

Positive antigen avoidance test

n

delta FVC %pred (%)

With treatment

7

0.4 ± 2.3

Without treatment

8

1.1 ± 2.1

Negative antigen avoidance test

n

delta FVC %pred (%)

With treatment

11

 − 3.0 ± 2.2

Without treatment

9

 − 7.5 ± 4.7

  1. Data are presented as mean ± standard error or n. The analysis of covariance was used with age, gender, and baseline FVC %pred as covariate
  2. FVC: forced vital capacity; %pred: % predicted